Login
4D Molecular Therapeutics, Inc. logo

4D Molecular Therapeutics, Inc.

4dmoleculartherapeutics.com

What Do They Do?

Develops genetic medicine candidates for people with retinal diseases and cystic fibrosis lung disease.

How Do They Make Money?

Partners pay upfront and license fees, fund research and development, and reimburse expenses; milestone payments and sales royalties may also come in. License fees are earned when the license begins, while research and development services are earned over the work period.

FY2025 revenue

Who Are Their Customers?

Otsuka receives licensed rights to develop and commercialize a retinal candidate in some Asia-Pacific markets; the Cystic Fibrosis Foundation funds development of a lung-disease candidate.

Do Revenues Turn Into Profits?

No. It lost $140.1M in FY2025.

Operating income, FY2025
−187% of revenue
▲ +15% (Loss) vs FY2024 (−$187.8M, −507678%)
Net income, FY2025
−164% of revenue
▲ +13% (Loss) vs FY2024 (−$160.9M, −434778%)
Free cash flow, FY2025
−129% of revenue
▲ +21% (Loss) vs FY2024 (−$138.4M, −373976%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +4506%
vs $90K in Q3 FY2025
Net income
▼ −37% (Loss)
vs −$56.9M in Q3 FY2025

Growing. Revenue grew 4.7x in 4 years, from $18M in FY2021 to $85.2M in FY2025, about 47% a year.

Partnered commercialization rights The older report describes the product-candidate pipeline as wholly owned; the latest describes Otsuka holding exclusive development and commercialization rights for a retinal candidate in some Asia-Pacific markets, while the company retains rights elsewhere.

A narrower stated development focus The older report describes candidates across eye, lung, and heart diseases; the latest centers its stated priorities on retinal disease and cystic fibrosis lung disease, with other programs advanced mainly through external funding.

Who Do They Compete With?

Competes with AbbVie, REGENXBIO, Adverum Biotechnologies, EyePoint, Ocular Therapeutix, Kodiak Sciences, Merck &, Regeneron Pharmaceuticals, Roche, Apellis Pharmaceuticals, Astellas Pharma, Vertex Pharmaceuticals, Sionna Therapeutics, Krystal Biotech, Arcturus Therapeutics Holdings, and Recode Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support